Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial.

Importance: There are no approved drug treatments for autosomal dominant retinitis pigmentosa, a relentlessly progressive cause of adult and childhood blindness.

Objectives: To evaluate the potential efficacy and assess the safety of orally administered valproic acid (VPA) in the treatment of autosomal dominant retinitis pigmentosa.

Design, Setting, And Participants: Multicenter, phase 2, prospective, interventional, placebo-controlled, double-masked randomized clinical trial.

Intravitreal Versus Subretinal Tissue Plasminogen Activator Injection for Submacular Hemorrhage.

Background And Objective: The objective of this study was to compare visual acuity outcomes between the following procedures used to treat submacular hemorrhages: pneumatic displacement followed by intravitreal tissue plasminogen activator (tPA) if needed (pneumatic ± tPA) and pars plana vitrectomy (PPV) with subretinal tPA (PPV + tPA).

Patients And Methods: This is a retrospective chart review of submacular hemorrhages treated with either pneumatic ± tPA or PPV + tPA.

Results: Eighteen patients had pneumatic ± tPA, and 14 patients had PPV + tPA.

Postcataract endophthalmitis caused by Mycobacterium goodii.

This is the first reported case of delayed-onset postcataract endophthalmitis caused by Mycobacterium goodii, confirmed by multiple cultures. The patient had uneventful cataract removal by phacoemulsification with implantation of a posterior chamber intraocular lens (IOL). One month later, he developed redness, pain, a hypopyon, and a decrease in visual acuity to finger counting in the affected eye.